Priovant Therapeutics
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. They are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for underserved patients.
Industries
Nr. of Employees
small (1-50)
Priovant Therapeutics
1007 Slater Road, Suite 250, Durham, NC 27703
Products
Clinical-stage oral dual JAK1/TYK2 small-molecule therapeutic (investigational)
An oral, once-daily small-molecule dual inhibitor of JAK1 and TYK2 developed as a clinical-stage therapeutic candidate for severe autoimmune diseases; tested in multiple Phase 2 studies and currently in Phase 3 trials for dermatomyositis and non-infectious uveitis.
Clinical-stage oral dual JAK1/TYK2 small-molecule therapeutic (investigational)
An oral, once-daily small-molecule dual inhibitor of JAK1 and TYK2 developed as a clinical-stage therapeutic candidate for severe autoimmune diseases; tested in multiple Phase 2 studies and currently in Phase 3 trials for dermatomyositis and non-infectious uveitis.
Services
Design and execution of global registrational clinical trials for severe autoimmune indications.
Policy-driven intake and evaluation process for individual patient requests to access investigational products outside clinical trials.
Preparation for and management of regulatory interactions, including seeking designations and coordinating with health authorities.
Design and execution of global registrational clinical trials for severe autoimmune indications.
Policy-driven intake and evaluation process for individual patient requests to access investigational products outside clinical trials.
Preparation for and management of regulatory interactions, including seeking designations and coordinating with health authorities.
Expertise Areas
- Clinical trial management
- Regulatory strategy and interactions
- CMC and drug product development
- Safety surveillance and pharmacovigilance
Key Technologies
- Dual JAK1/TYK2 small-molecule kinase inhibition
- Oral small-molecule therapeutic development
- Global Phase 2/Phase 3 clinical trial operations
- In vitro cell-based pharmacology assays